Feasibility and Advantage of Adding 131i-Mibg to 90y-Dotatoc for Treatment of Patients With Advanced Stage Neuroendocrine Tumors
EJNMMI Research - Germany
doi 10.1186/s13550-014-0038-2
Full Text
Open PDFAbstract
Available in full text
Date
September 10, 2014
Authors
Publisher
Springer Science and Business Media LLC